Researchers from Connecta Therapeutics SL and the Centre for Genomic Regulation (Barcelona Institute of Science and Technology) recently presented preclinical results on CTH-120, a potential first-in-class allosteric modulator of tropomyosin receptor kinase B (TrkB) designed to enhance neuroplasticity and restore neuronal function in fragile X syndrome.